10.6084/m9.figshare.4539856.v2
Wanchoo R.
Wanchoo
R.
Karam S.
Karam
S.
Uppal N.N.
Uppal
N.N.
Barta V.S.
Barta
V.S.
Deray G.
Deray
G.
Devoe C.
Devoe
C.
Launay-Vacher V.
Launay-Vacher
V.
Jhaveri K.D.
Jhaveri
K.D.
on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint
Inhibitors
Supplementary Material for: Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Karger Publishers
2017
Renal failure
Acute interstitial nephritis
Ipilimumab
Nivolumab
Onconephrology
Pembrolizumab
Targeted therapies
2017-01-23 07:27:01
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Adverse_Renal_Effects_of_Immune_Checkpoint_Inhibitors_A_Narrative_Review/4539856
<p><b><i>Background:</i></b> Cancer immunotherapy, such as
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and
anti-programmed death 1 (PD-1), has revolutionized the treatment of
malignancies by engaging the patient's own immune system against the
tumor rather than targeting the cancer directly. These therapies have
demonstrated a significant benefit in the treatment of melanomas and
other cancers. <b><i>Summary:</i></b> In order to provide an extensive
overview of the renal toxicities induced by these agents, a Medline
search was conducted of published literature related to ipilimumab-,
pembrolizumab-, and nivolumab-induced kidney toxicity. In addition,
primary data from the initial clinical trials of these agents and the
FDA adverse reporting system database were also reviewed to determine
renal adverse events. Acute interstitial nephritis (AIN), podocytopathy,
and hyponatremia were toxicities caused by ipilimumab. The main adverse
effect associated with both the PD-1 inhibitors was AIN. The onset of
kidney injury seen with PD-1 inhibitors is usually late (3-10 months)
compared to CTLA-4 antagonists related renal injury, which happens
earlier (2-3 months). PD-1 as opposed to CTLA-4 inhibitors has been
associated with kidney rejection in transplantation. Steroids appear to
be effective in treating the immune-related adverse effects noted with
these agents. <b><i>Key Message:</i></b> Although initially thought to
be rare, the incidence rates of renal toxicities might be higher
(9.9-29%) as identified by recent studies. As a result, obtaining
knowledge about renal toxicities of immune checkpoint inhibitors is
extremely important.</p>